Intelligence Briefing · ~5 min read
New Generic Entry for Diphenhydramine Hydrochloride Alters Antihistamine Market Dynamics
Allergy · Antihistamine
Type
Regulatory Context BriefingGenerated
Jul 23, 2026
Confidence
Moderate Confidence · 72%
Evidence
6 items
Sources
6
Key Takeaways
Leadership-ready summary — read in 5 minutes.
- Regulatory risk is concentrated around FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG) (FDA). Entity match (annora pharma); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest any immediate regulatory changes for existing products.
- Regulatory scrutiny on pricing practices may increase as competition intensifies.
- Competitive pressure on Annora Pharma: This approval allows Annora Pharma to enter the market with a generic antihistamine, potentially increasing competition.
Why It Matters
Strategic context for leadership and portfolio decision-making.
Regulatory risk is concentrated around FDA AP — DIPHENHYDRAMINE HYDROCHLORIDE (ORIG) (FDA). Entity match (annora pharma); Regulatory pathway relevance (nda). The approval indicates compliance with FDA standards, but does not suggest any immediate regulatory changes for existing products.
Supporting Evidence
Evidence-backed items from the Humanexa intelligence graph.
FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470
Allergy · Antihistamine
Source: Regulatory Approval
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- FDA Grants Approval for Diphenhydramine Hydrochloride ANDA219470
Allergy · Antihistamine
Insights
- New Generic Entry for Diphenhydramine Hydrochloride Alters Antihistamine Market Dynamics
Allergy · Antihistamine